Key result
Intermittent SVC occlusion via preCARDIA is linked to reduced wedge pressures and 0 HF readmissions.
Why the study?
Does intermittent superior vena cava occlusion using the preCARDIA system improve hemodynamics and reduce readmissions in patients with acute decompensated heart failure?
Observational
No
Does intermittent superior vena cava occlusion using the preCARDIA system improve hemodynamics and reduce readmissions in patients with acute decompensated heart failure?
Intermittent superior vena cava occlusion using the preCARDIA system may offer a safe mechanical diuretic strategy for managing acute decompensated heart failure.
May support intermittent SVC occlusion as a mechanical diuretic in ADHF; hypothesis-generating and should not yet change practice.
The preCARDIA system is a device combining a balloon-mounted catheter and an extracorporeal system designed for intermittent occlusion of the superior vena cava. Studies have established safety and efficacy in acute decompensated heart failure. We present a single-center experience detailing 90 days outcomes and procedural insights. A 24 hours therapy session demonstrated reduced pulmonary wedge pressures and increased urine output, with cardiac output remaining unchanged. There was one readmission and no heart failure-related readmissions at 90 days. The preCARDIA device appears to be a safe mechanical diuretic strategy to manage patients with acute decompensated heart failure beyond current therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Yousefzai et al. (2023) conducted an observational in Acute decompensated heart failure. preCARDIA system was evaluated on 90 days outcomes and procedural insights. The preCARDIA system for intermittent superior vena cava occlusion reduced pulmonary wedge pressures and increased urine output over 24 hours, with no heart failure-related readmissions at 90 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: